Envista Holdings Corp NVST
We take great care to ensure that the data presented and summarized in this overview for Envista Holdings Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVST
View all-
Black Rock Inc. New York, NY19.5MShares$397 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.1MShares$348 Million0.01% of portfolio
-
Morgan Stanley New York, NY13.8MShares$282 Million0.02% of portfolio
-
Ariel Investments, LLC Chicago, IL12.1MShares$248 Million2.72% of portfolio
-
Atlanta Capital Management CO L L C Atlanta, GA10.5MShares$213 Million1.53% of portfolio
-
Harris Associates L P Chicago, IL8.68MShares$177 Million0.27% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.39MShares$171 Million0.04% of portfolio
-
Franklin Resources Inc San Mateo, CA7.67MShares$156 Million0.04% of portfolio
-
American Century Companies Inc Kansas City, MO6.35MShares$129 Million0.07% of portfolio
-
State Street Corp Boston, MA5.68MShares$116 Million0.0% of portfolio
Latest Institutional Activity in NVST
Top Purchases
Top Sells
About NVST
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands. This segment also offers software packages, which include DTX Studio Implant for treatment planning of dental implants; TX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic to store and access a various clinical patient images. The company's Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, sensors, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Insider Transactions at NVST
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 10
2025
|
R Scott Huennekens Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,370
+17.13%
|
-
|
Jun 10
2025
|
Barbara B. Hulit Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+11.58%
|
-
|
Jun 10
2025
|
Christine A Tsingos Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+17.12%
|
-
|
Jun 10
2025
|
Wendy Carruthers Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+17.11%
|
-
|
Jun 10
2025
|
Vivek Jain Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+19.33%
|
-
|
Jun 10
2025
|
Daniel Raskas Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+18.96%
|
-
|
Jun 10
2025
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,450
+18.96%
|
-
|
May 25
2025
|
Paul A Keel Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,787
-3.09%
|
$204,592
$16.72 P/Share
|
Feb 26
2025
|
Mischa Reis SVP, Strategy & Bus. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
8,475
+15.17%
|
-
|
Feb 25
2025
|
Mark E Nance General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
18,155
+20.15%
|
-
|
Feb 25
2025
|
Mark E Nance General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,691
-6.42%
|
$73,820
$20.66 P/Share
|
Feb 25
2025
|
Eric D. Hammes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,735
+13.09%
|
-
|
Feb 25
2025
|
Robert Befidi President, Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
10,290
+17.37%
|
-
|
Feb 25
2025
|
Robert Befidi President, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,123
-2.82%
|
$22,460
$20.66 P/Share
|
Feb 25
2025
|
Stefan Nilsson President, Nobel Biocare |
BUY
Grant, award, or other acquisition
|
Direct |
10,290
+15.58%
|
-
|
Feb 25
2025
|
Veronica Acurio President, Orthodontics |
BUY
Grant, award, or other acquisition
|
Direct |
10,290
+15.58%
|
-
|
Feb 25
2025
|
Paul A Keel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,830
+13.71%
|
-
|
Feb 25
2025
|
Mischa Reis SVP, Strategy & Bus. Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,813
-8.93%
|
$76,260
$20.66 P/Share
|
Feb 25
2025
|
Faez C Kaabi Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,685
+16.23%
|
-
|
Feb 25
2025
|
Faez C Kaabi Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,319
-9.68%
|
$86,380
$20.66 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 290K shares |
---|---|
Open market or private purchase | 54.5K shares |
Payment of exercise price or tax liability | 84.5K shares |
---|